Latest breakthroughs in cancer research, treatment, and prevention
497 articles
A tryptophan-derived gut metabolite suppresses colorectal cancer by blocking a key glycolysis enzyme via STAT3 inhibition.
A newly discovered bacteriophage inside common gut bacteria appears strongly linked to colorectal cancer, potentially explaining a long-standing medical paradox.
PQQ, a widely available dietary supplement, inhibits EZH2 and suppresses B-cell lymphoma proliferation in lab studies.
A sweeping 2025 review maps how gut, tumor, and systemic microbiomes promote or suppress cancer across every major tumor type.
A comprehensive review reveals how intracellular bacteria colonize cancer cells, fuel metastasis, and can be weaponized against tumors.
Engineered magnetotactic bacteria delivered orally penetrate colorectal tumors, trigger immune attack, and reshape gut microbial metabolism in mice.
A gut metabolite produced after chemo reprograms bone marrow immune cells, creating a lasting shield against colorectal cancer liver metastasis.
A protein called HOXD13 drives skin cancer growth and shields tumors from immune cells — disabling it could unlock powerful new treatments.
A Nature study reveals lung tumors activate vagal nerves to drive sympathetic signaling that shuts down anti-tumor immunity.
Neuronal signals fuel small cell lung cancer via the vagus nerve and direct neuron-to-tumor synapses, opening new therapeutic targets.
A landmark screen of approved kinase inhibitors reveals 94% of cancer mutations are already targetable — and uncovers surprising new drug uses.
Zongertinib (Hernexeos) wins FDA accelerated approval for HER2-driven non-small cell lung cancer, offering a targeted oral option.
